Insulin detemir
- Generic Name
- Insulin detemir
- Brand Names
- Levemir
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 169148-63-4
- Unique Ingredient Identifier
- 4FT78T86XV
- Background
Insulin detemir is a long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas that promotes glucose metabolism. Insulin ...
- Indication
Insulin detemir is indicated to improve glycemic control in adults and children with diabetes mellitus.
- Associated Conditions
- Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
- Associated Therapies
- -
Efficacy and Safety of Insulin Detemir Versus Neutral Protamine Hagedorn (NPH) Insulin in Pregnant Women With Type 1 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2007-05-16
- Last Posted Date
- 2017-03-10
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 470
- Registration Number
- NCT00474045
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Watford, United Kingdom
A Comparison Between Glargine and Detemir Insulin in Type 2 Diabetes
- Conditions
- First Posted Date
- 2007-04-05
- Last Posted Date
- 2010-11-18
- Lead Sponsor
- Diabetes Care Center
- Target Recruit Count
- 35
- Registration Number
- NCT00457093
- Locations
- 🇺🇸
Diabetes Care Center, Salinas, California, United States
Evaluation of the Glycaemic Control With Insulin Detemir as an add-on to Current Oral Anti-diabetic Drug Treatment in Subjects With Type 2 Diabetes in Korea
- First Posted Date
- 2007-04-04
- Last Posted Date
- 2024-02-01
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 87
- Registration Number
- NCT00455858
Safety of Insulin Detemir Produced by a New Process as Measured by Antibody Formation in Subjects With Type 1 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2007-03-14
- Last Posted Date
- 2024-01-02
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 330
- Registration Number
- NCT00447382
Comparison of NPH Insulin and Insulin Detemir in Children and Adolescents With Type 1 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2007-02-14
- Last Posted Date
- 2017-03-10
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 348
- Registration Number
- NCT00435019
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Norfolk, United Kingdom
Lantus Versus Levemir Treat-To-Target
- Conditions
- Interventions
- First Posted Date
- 2006-11-30
- Last Posted Date
- 2009-09-15
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 973
- Registration Number
- NCT00405418
- Locations
- 🇬🇧
Sanofi-Aventis, Guildford, United Kingdom
Effect of Insulin Detemir on Blood Glucose Control in Subjects With Type 2 Diabetes
- Conditions
- First Posted Date
- 2006-10-04
- Last Posted Date
- 2024-01-02
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 263
- Registration Number
- NCT00383877
Safety and Efficacy of Inhaled Insulin in Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2006-05-31
- Last Posted Date
- 2017-03-01
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 618
- Registration Number
- NCT00331604
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Wirral, Merseyside, United Kingdom
Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2006-05-05
- Last Posted Date
- 2018-09-05
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 596
- Registration Number
- NCT00322257
- Locations
- 🇨🇦
Novo Nordisk Investigational Site, Vancouver, Canada
The Effect of Exercise on Blood Glucose Levels in Patients With Type 1 Diabetes: A Comparison of 3 Long-acting Insulins
- Conditions
- First Posted Date
- 2006-04-12
- Last Posted Date
- 2023-11-02
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 51
- Registration Number
- NCT00313742
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.